Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02568553 · ClinicalTrials.gov registry record · Phase 1
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT02568553: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT02568553 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 35 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02568553, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of lenalidomide and blinatumomab when given together in treating patients with non-Hodgkin lymphoma that has returned after a period of improvement (relapsed). Biological therapies, such as lenalidomide, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Blinatumomab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread.
Interventions
- DRUG Lenalidomide
- BIOLOGICAL Blinatumomab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2016-11-15 |
| Est. Completion | 2025-11-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02568553
The ClinicalTrials.gov registry entry for NCT02568553 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lenalidomide is the first listed.
NCT02568553 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02568553 about?
NCT02568553 is a clinical study titled "Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma". This phase I trial studies the side effects and best dose of lenalidomide and blinatumomab when given together in treating patients with non-Hodgkin lymphoma that has returned after a period of improvement (relapsed). Biological therapies, such as lenalidomide, use substances made from living organi...
What is the current status of trial NCT02568553?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2016-11-15. Estimated completion is 2025-11-24.
What interventions are being tested in trial NCT02568553?
The interventions under investigation include: Lenalidomide (DRUG), Blinatumomab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02568553?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.